Key result
Optimal management of concomitant CAD remains uncertain despite affecting ~50% of TAVI patients.
Why the study?
Despite the high prevalence of coronary artery disease in patients treated with TAVI, the management strategy of concomitant CAD remains an area of considerable uncertainty.
This review provides an updated overview of the current knowledge and points for reflection regarding the management of concomitant coronary artery disease in patients undergoing TAVI.
Management of concomitant CAD in TAVI patients should remain individualized; leaves open need for definitive RCTs.
Severe calcific aortic stenosis (AS) and coronary artery disease (CAD) have common risk factors and are frequently encountered in the same patient in clinical practice. CAD has been reported in ≥ 50% of AS patients undergoing both surgical treatment and transcatheter aortic valve implantation (TAVI). In the last two decades, TAVI has been established as a less invasive alternative to surgery. Recently, more and more young and low surgical risk patients undergo TAVI. Despite the high prevalence of CAD in patients treated with TAVI, the management strategy of concomitant CAD in these patients remains an area of considerable uncertainty. This review provides an updated overview of the current knowledge about this topic and offers points for reflection about the best approach to use.
No takes yet. Share an insight, caveat, or question.
Cangemi et al. (2022) conducted a review in Severe calcific aortic stenosis and coronary artery disease. Management of concomitant coronary artery disease was evaluated. Coronary artery disease is present in ≥50% of patients with aortic stenosis undergoing TAVI, yet the optimal management strategy for concomitant CAD in this population remains uncertain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: